Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI 96813, USA.
Cancer Causes Control. 2010 Oct;21(10):1731-41. doi: 10.1007/s10552-010-9602-x. Epub 2010 Jun 18.
Inflammation is postulated to play an important role in ovarian carcinogenesis. Prostaglandin endoperoxide synthase 2 (PTGS2) is responsible for the conversion of arachidonic acid to prostaglandins in response to inflammation. In a pooled analysis of two population-based studies, the Hawaii Ovarian Cancer Case-Control Study and the New England Case-Control Study, including 1,025 women with invasive ovarian carcinoma and 1,687 cancer-free controls, the association of ovarian cancer risk with the PTGS2 rs5275 polymorphism and the use of nonsteroidal antiinflammatory drugs (NSAIDs) were examined. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. In the pooled analysis, the CC genotype was associated with a reduced risk of nonserous ovarian carcinoma (OR = 0.66; CI: 0.44-0.98). In addition, the lowest risk was observed among carriers of the CC genotype who were users of only nonaspirin NSAIDs (OR = 0.43; CI:0.20-0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies.
炎症被认为在卵巢癌的发生中起着重要作用。前列腺素内过氧化物合酶 2（PTGS2）负责将花生四烯酸转化为前列腺素，以响应炎症。在两项基于人群的研究——夏威夷卵巢癌病例对照研究和新英格兰病例对照研究的汇总分析中，包括 1025 名侵袭性卵巢癌患者和 1687 名无癌症对照者，研究了卵巢癌风险与 PTGS2 rs5275 多态性和非甾体抗炎药（NSAIDs）使用之间的关联。使用无条件逻辑回归估计比值比（OR）和 95%置信区间（CI）。在汇总分析中，CC 基因型与非浆液性卵巢癌的风险降低相关（OR=0.66；CI：0.44-0.98）。此外，在所有女性中，仅使用非阿司匹林类 NSAIDs 的 CC 基因型携带者的风险最低（OR=0.43；CI：0.20-0.93）。PTGS2 rs5275 与非浆液性卵巢癌的关联以及 NSAID 使用的可能修饰作用需要进一步验证，最好在前瞻性研究中进行。
